A Study of the Safety and Effectiveness of JNJ-39758979 in the Treatment of Adults With Persistent Asthma

• Status: Completed
• Trial end date: 2010-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety and effectiveness of once daily oral administration of JNJ-39758979 in the treatment of adults (18 to 65 years of age) with persistent asthma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Criteria

Inclusion Criteria:

• Confirmed diagnosis of asthma for at least 6 months

• Short-acting beta-agonist use greater than or equal to 5 times in the 2 weeks prior to screening

• Healthy on the basis of physical examination, medical history, vital signs, and 12 lead ECG performed at screening

• Having adequate laboratory values

• No history of/active or latent tuberculosis

• Agree to use protocol defined contraceptive methods

Exclusion Criteria:

• History of life-threatening asthma attack requiring hospitalization for asthma within 5 years of screening, or emergency department treatment of asthma within the last month

• Moderate or severe renal insufficiency

• Cigarette smoking within the last year - Viral or bacterial vaccination within the last month (eg, FluMist)

• Human Immunodeficiency Virus (HIV) or Hepatitis B or C positive